May 28, 2024

Medical Trend

Medical News and Medical Resources

How about bone marrow suppression after tumor chemotherapy?

How about bone marrow suppression after tumor chemotherapy?


How about bone marrow suppression after tumor chemotherapy? New long-acting white blood cell-boosting drugs are here, so you might as well understand. 

How about bone marrow suppression after tumor chemotherapy?

Everyone knows that chemotherapy is one of the most important methods of tumor treatment. In many people’s impressions, patients will experience hair loss, nausea and vomiting, and extreme loss of appetite after chemotherapy. It is very hard, but in fact, it is the most difficult for clinicians. To deal with the bone marrow suppression caused by chemotherapeutics. Bone marrow suppression can cause agranulocytosis and a decrease in white blood cells in patients, even to zero in some patients.

Granulocytes are the body’s defensive cells, that is, immune cells. When granulocytes are reduced to zero, it means that the body has completely lost immunity. At this time, the human body is easily affected by bacteria, viruses or other existing external or internal bacteria. Pathogens are infected and even die as a result. However, clinicians are not completely helpless with myelosuppression. Shengbai needle recombinant human granulocyte stimulating factor is the best weapon for clinicians to deal with myelosuppression. In recent years, some countries has launched a longer-acting long-acting Shengbai needle Xinruibai. , I will introduce to you today.


The characteristics and clinical application of long-acting Shengbai Needle

Long-acting Shengbai Needle, also known as long-acting recombinant human granulocyte stimulating factor, is made by covalently combining with polyethylene glycol using genetic recombination technology. Compared with the traditional short-acting white-lifting needle, the long-acting white-lifting needle has longer action time, more stable plasma concentration, and significantly reduced immunogenicity and antigenicity. It is not easy to produce neutralizing antibodies, that is, the body is not easy to produce drug resistance. specialty.

In clinical application, a chemotherapy cycle only needs to be injected once, which can save the patient from the need for repeated injections of short-acting whitening needles and frequent blood draws to recheck blood routines during the chemotherapy cycle. It can be said that it is more suitable for agranulocytosis after tumor chemotherapy. Used by patients. However, it should be noted that no matter whether it is short-acting or long-acting Shengbai needle, it is not recommended to use it during chemotherapy, because the hematopoietic function of bone marrow is more susceptible to chemotherapy drugs after being activated by Shengbai needle. To increase the effect of white blood cells, it will worsen the hematopoietic function. Therefore, the Shengbai needle should be used prophylactically before chemotherapy or therapeutically after chemotherapy according to the specific conditions of the patient.

In addition, due to the short time to market, the current price of long-acting Shengbai needle is relatively high, which is also the main reason that restricts its large-scale clinical application.


Comparison of curative effect between long-acting whitening needle and short-acting whitening needle

Having said so many theories, although everyone knows that long-acting whitening needles are better, but as the saying goes, “It’s the mule that pulls out from the horse.” Therefore, some scholars take breast cancer chemotherapy patients as the research object and compare the use of long-acting after chemotherapy. Clinical efficacy of Shengbai Needle and Short-acting Shengbai Needle.

The results showed that the number of neutropenia and concurrent infections in the case group using the long-acting Shengbai needle during the intermittent period of chemotherapy was significantly less than that of the short-acting Shengbai needle group, and the clinical effect was definite. Another multi-center post-marketing clinical study conducted in some countries also found that the use of long-acting Shengbai needles can significantly reduce the incidence of severe agranulocytosis in chemotherapy patients, and the complications of agranulocytosis and fever are also significantly reduced.


In short, the long-acting Shengbai needle is undoubtedly a more suitable drug for patients with agranulocytosis after chemotherapy. We also expect that its price will be more affordable in the near future, and it will become a good medicine that everyone can afford.


(source:internet, reference only)

Disclaimer of